Immunological Patient Stratification in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease characterized by profound fatigue, post-exertional malaise (PEM), and neurocognitive dysfunction. Immune dysregulation and gastrointestinal symptoms are commonly observed in ME/CFS patients. Despite affecting approximat...
Gespeichert in:
Veröffentlicht in: | Journal of clinical medicine 2024-01, Vol.13 (1), p.275 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 1 |
container_start_page | 275 |
container_title | Journal of clinical medicine |
container_volume | 13 |
creator | Rohrhofer, Johanna Hauser, Lisa Lettenmaier, Lisa Lutz, Lena Koidl, Larissa Gentile, Salvatore Alessio Ret, Davide Stingl, Michael Untersmayr, Eva |
description | Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease characterized by profound fatigue, post-exertional malaise (PEM), and neurocognitive dysfunction. Immune dysregulation and gastrointestinal symptoms are commonly observed in ME/CFS patients. Despite affecting approximately 0.89% of the general population, the underlying pathophysiological mechanisms remain poorly understood. This study aimed to elucidate the relationship between immunological characteristics and intestinal barrier function in ME/CFS patients. ME/CFS patients were stratified into two groups based on their immune competence. After documentation of detailed medical records, serum and plasma samples were collected for the assessment of inflammatory immune mediators and biomarkers for intestinal barrier integrity by ELISA. We found reduced complement protein C4a levels in immunodeficient ME/CFS patients suggesting a subgroup-specific innate immune dysregulation. ME/CFS patients without immunodeficiencies exhibit a mucosal barrier leakage, as indicated by elevated levels of Lipopolysaccharide-binding protein (LBP). Stratifying ME/CFS patients based on immune competence enabled the distinction of two subgroups with different pathophysiological patterns. The study highlights the importance of emphasizing precise patient stratification in ME/CFS, particularly in the context of defining suitable treatment strategies. Given the substantial health and socioeconomic burden associated with ME/CFS, urgent attention and research efforts are needed to define causative treatment approaches. |
doi_str_mv | 10.3390/jcm13010275 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10779792</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A779345788</galeid><sourcerecordid>A779345788</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-7978d9651d092f96090cd8d396b22ea6233bb2a718dee76e0271f65067a896e03</originalsourceid><addsrcrecordid>eNpdkUtLAzEQgIMoKurJuyx4EaSaR3eTnERKfYCioF68hDSbbVOySU12hf57p_iq5pLHfHwzk0HokOAzxiQ-n5uWMEww5eUG2qWY8wFmgm2unXfQQc5zDEuIISV8G-0wQTGlgu6i19u27UP0ceqM9sWj7pwNXfHUJTg18Na5GAoXivul9sAU42DsYqZ9bJfWu87l89EsxQCRK2CnvS2elqFOsbX7aKvRPtuDr30PvVyNn0c3g7uH69vR5d3ADJnoBlxyUcuqJDWWtJEVltjUomaymlBqdUUZm0yo5kTU1vLKQqukqUpccS0kXNkeuvj0LvpJa2sD9Sft1SK5Vqelitqpv5HgZmoa3xWBH5JcUjCcfBlSfOtt7lTrsrHe62BjnxWVhA1LKE8AevwPncc-BehvRdEKhGX5S021t8qFJkJis5KqS8gJMi5WrtNPyqSYc7LNT80Eq9V01dp0gT5ab_OH_Z4l-wBYtp8M</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2912679755</pqid></control><display><type>article</type><title>Immunological Patient Stratification in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Rohrhofer, Johanna ; Hauser, Lisa ; Lettenmaier, Lisa ; Lutz, Lena ; Koidl, Larissa ; Gentile, Salvatore Alessio ; Ret, Davide ; Stingl, Michael ; Untersmayr, Eva</creator><creatorcontrib>Rohrhofer, Johanna ; Hauser, Lisa ; Lettenmaier, Lisa ; Lutz, Lena ; Koidl, Larissa ; Gentile, Salvatore Alessio ; Ret, Davide ; Stingl, Michael ; Untersmayr, Eva</creatorcontrib><description>Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease characterized by profound fatigue, post-exertional malaise (PEM), and neurocognitive dysfunction. Immune dysregulation and gastrointestinal symptoms are commonly observed in ME/CFS patients. Despite affecting approximately 0.89% of the general population, the underlying pathophysiological mechanisms remain poorly understood. This study aimed to elucidate the relationship between immunological characteristics and intestinal barrier function in ME/CFS patients. ME/CFS patients were stratified into two groups based on their immune competence. After documentation of detailed medical records, serum and plasma samples were collected for the assessment of inflammatory immune mediators and biomarkers for intestinal barrier integrity by ELISA. We found reduced complement protein C4a levels in immunodeficient ME/CFS patients suggesting a subgroup-specific innate immune dysregulation. ME/CFS patients without immunodeficiencies exhibit a mucosal barrier leakage, as indicated by elevated levels of Lipopolysaccharide-binding protein (LBP). Stratifying ME/CFS patients based on immune competence enabled the distinction of two subgroups with different pathophysiological patterns. The study highlights the importance of emphasizing precise patient stratification in ME/CFS, particularly in the context of defining suitable treatment strategies. Given the substantial health and socioeconomic burden associated with ME/CFS, urgent attention and research efforts are needed to define causative treatment approaches.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm13010275</identifier><identifier>PMID: 38202282</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Chronic fatigue syndrome ; COVID-19 ; Development and progression ; Disease ; Encephalomyelitis ; Enzyme-linked immunosorbent assay ; Females ; Hypotheses ; Immunodeficiency ; Immunology ; Infections ; Irritable bowel syndrome ; Medical records ; Patients ; Protein binding ; Severe acute respiratory syndrome coronavirus 2 ; Tumor necrosis factor-TNF ; Viral infections</subject><ispartof>Journal of clinical medicine, 2024-01, Vol.13 (1), p.275</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-7978d9651d092f96090cd8d396b22ea6233bb2a718dee76e0271f65067a896e03</citedby><cites>FETCH-LOGICAL-c438t-7978d9651d092f96090cd8d396b22ea6233bb2a718dee76e0271f65067a896e03</cites><orcidid>0000-0002-2783-2099 ; 0000-0002-7461-0923 ; 0000-0002-1963-499X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10779792/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10779792/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38202282$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rohrhofer, Johanna</creatorcontrib><creatorcontrib>Hauser, Lisa</creatorcontrib><creatorcontrib>Lettenmaier, Lisa</creatorcontrib><creatorcontrib>Lutz, Lena</creatorcontrib><creatorcontrib>Koidl, Larissa</creatorcontrib><creatorcontrib>Gentile, Salvatore Alessio</creatorcontrib><creatorcontrib>Ret, Davide</creatorcontrib><creatorcontrib>Stingl, Michael</creatorcontrib><creatorcontrib>Untersmayr, Eva</creatorcontrib><title>Immunological Patient Stratification in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease characterized by profound fatigue, post-exertional malaise (PEM), and neurocognitive dysfunction. Immune dysregulation and gastrointestinal symptoms are commonly observed in ME/CFS patients. Despite affecting approximately 0.89% of the general population, the underlying pathophysiological mechanisms remain poorly understood. This study aimed to elucidate the relationship between immunological characteristics and intestinal barrier function in ME/CFS patients. ME/CFS patients were stratified into two groups based on their immune competence. After documentation of detailed medical records, serum and plasma samples were collected for the assessment of inflammatory immune mediators and biomarkers for intestinal barrier integrity by ELISA. We found reduced complement protein C4a levels in immunodeficient ME/CFS patients suggesting a subgroup-specific innate immune dysregulation. ME/CFS patients without immunodeficiencies exhibit a mucosal barrier leakage, as indicated by elevated levels of Lipopolysaccharide-binding protein (LBP). Stratifying ME/CFS patients based on immune competence enabled the distinction of two subgroups with different pathophysiological patterns. The study highlights the importance of emphasizing precise patient stratification in ME/CFS, particularly in the context of defining suitable treatment strategies. Given the substantial health and socioeconomic burden associated with ME/CFS, urgent attention and research efforts are needed to define causative treatment approaches.</description><subject>Chronic fatigue syndrome</subject><subject>COVID-19</subject><subject>Development and progression</subject><subject>Disease</subject><subject>Encephalomyelitis</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Females</subject><subject>Hypotheses</subject><subject>Immunodeficiency</subject><subject>Immunology</subject><subject>Infections</subject><subject>Irritable bowel syndrome</subject><subject>Medical records</subject><subject>Patients</subject><subject>Protein binding</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Tumor necrosis factor-TNF</subject><subject>Viral infections</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkUtLAzEQgIMoKurJuyx4EaSaR3eTnERKfYCioF68hDSbbVOySU12hf57p_iq5pLHfHwzk0HokOAzxiQ-n5uWMEww5eUG2qWY8wFmgm2unXfQQc5zDEuIISV8G-0wQTGlgu6i19u27UP0ceqM9sWj7pwNXfHUJTg18Na5GAoXivul9sAU42DsYqZ9bJfWu87l89EsxQCRK2CnvS2elqFOsbX7aKvRPtuDr30PvVyNn0c3g7uH69vR5d3ADJnoBlxyUcuqJDWWtJEVltjUomaymlBqdUUZm0yo5kTU1vLKQqukqUpccS0kXNkeuvj0LvpJa2sD9Sft1SK5Vqelitqpv5HgZmoa3xWBH5JcUjCcfBlSfOtt7lTrsrHe62BjnxWVhA1LKE8AevwPncc-BehvRdEKhGX5S021t8qFJkJis5KqS8gJMi5WrtNPyqSYc7LNT80Eq9V01dp0gT5ab_OH_Z4l-wBYtp8M</recordid><startdate>20240103</startdate><enddate>20240103</enddate><creator>Rohrhofer, Johanna</creator><creator>Hauser, Lisa</creator><creator>Lettenmaier, Lisa</creator><creator>Lutz, Lena</creator><creator>Koidl, Larissa</creator><creator>Gentile, Salvatore Alessio</creator><creator>Ret, Davide</creator><creator>Stingl, Michael</creator><creator>Untersmayr, Eva</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2783-2099</orcidid><orcidid>https://orcid.org/0000-0002-7461-0923</orcidid><orcidid>https://orcid.org/0000-0002-1963-499X</orcidid></search><sort><creationdate>20240103</creationdate><title>Immunological Patient Stratification in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome</title><author>Rohrhofer, Johanna ; Hauser, Lisa ; Lettenmaier, Lisa ; Lutz, Lena ; Koidl, Larissa ; Gentile, Salvatore Alessio ; Ret, Davide ; Stingl, Michael ; Untersmayr, Eva</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-7978d9651d092f96090cd8d396b22ea6233bb2a718dee76e0271f65067a896e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Chronic fatigue syndrome</topic><topic>COVID-19</topic><topic>Development and progression</topic><topic>Disease</topic><topic>Encephalomyelitis</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Females</topic><topic>Hypotheses</topic><topic>Immunodeficiency</topic><topic>Immunology</topic><topic>Infections</topic><topic>Irritable bowel syndrome</topic><topic>Medical records</topic><topic>Patients</topic><topic>Protein binding</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Tumor necrosis factor-TNF</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rohrhofer, Johanna</creatorcontrib><creatorcontrib>Hauser, Lisa</creatorcontrib><creatorcontrib>Lettenmaier, Lisa</creatorcontrib><creatorcontrib>Lutz, Lena</creatorcontrib><creatorcontrib>Koidl, Larissa</creatorcontrib><creatorcontrib>Gentile, Salvatore Alessio</creatorcontrib><creatorcontrib>Ret, Davide</creatorcontrib><creatorcontrib>Stingl, Michael</creatorcontrib><creatorcontrib>Untersmayr, Eva</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rohrhofer, Johanna</au><au>Hauser, Lisa</au><au>Lettenmaier, Lisa</au><au>Lutz, Lena</au><au>Koidl, Larissa</au><au>Gentile, Salvatore Alessio</au><au>Ret, Davide</au><au>Stingl, Michael</au><au>Untersmayr, Eva</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunological Patient Stratification in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2024-01-03</date><risdate>2024</risdate><volume>13</volume><issue>1</issue><spage>275</spage><pages>275-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease characterized by profound fatigue, post-exertional malaise (PEM), and neurocognitive dysfunction. Immune dysregulation and gastrointestinal symptoms are commonly observed in ME/CFS patients. Despite affecting approximately 0.89% of the general population, the underlying pathophysiological mechanisms remain poorly understood. This study aimed to elucidate the relationship between immunological characteristics and intestinal barrier function in ME/CFS patients. ME/CFS patients were stratified into two groups based on their immune competence. After documentation of detailed medical records, serum and plasma samples were collected for the assessment of inflammatory immune mediators and biomarkers for intestinal barrier integrity by ELISA. We found reduced complement protein C4a levels in immunodeficient ME/CFS patients suggesting a subgroup-specific innate immune dysregulation. ME/CFS patients without immunodeficiencies exhibit a mucosal barrier leakage, as indicated by elevated levels of Lipopolysaccharide-binding protein (LBP). Stratifying ME/CFS patients based on immune competence enabled the distinction of two subgroups with different pathophysiological patterns. The study highlights the importance of emphasizing precise patient stratification in ME/CFS, particularly in the context of defining suitable treatment strategies. Given the substantial health and socioeconomic burden associated with ME/CFS, urgent attention and research efforts are needed to define causative treatment approaches.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38202282</pmid><doi>10.3390/jcm13010275</doi><orcidid>https://orcid.org/0000-0002-2783-2099</orcidid><orcidid>https://orcid.org/0000-0002-7461-0923</orcidid><orcidid>https://orcid.org/0000-0002-1963-499X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2077-0383 |
ispartof | Journal of clinical medicine, 2024-01, Vol.13 (1), p.275 |
issn | 2077-0383 2077-0383 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10779792 |
source | MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
subjects | Chronic fatigue syndrome COVID-19 Development and progression Disease Encephalomyelitis Enzyme-linked immunosorbent assay Females Hypotheses Immunodeficiency Immunology Infections Irritable bowel syndrome Medical records Patients Protein binding Severe acute respiratory syndrome coronavirus 2 Tumor necrosis factor-TNF Viral infections |
title | Immunological Patient Stratification in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T03%3A46%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunological%20Patient%20Stratification%20in%20Myalgic%20Encephalomyelitis/Chronic%20Fatigue%20Syndrome&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Rohrhofer,%20Johanna&rft.date=2024-01-03&rft.volume=13&rft.issue=1&rft.spage=275&rft.pages=275-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm13010275&rft_dat=%3Cgale_pubme%3EA779345788%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2912679755&rft_id=info:pmid/38202282&rft_galeid=A779345788&rfr_iscdi=true |